Oric Pharmaceuticals, Inc. last reported quarterly results on Aug 3, 2026, for Q2 FY2026 (the quarter ended Jun 30, 2026): diluted EPS of -$0.38. It usually reports 34–54 days after a quarter ends. Based on that pattern, the next release is estimated for around Nov 12, 2026.
Results for Q3 FY2026, the quarter ending around Sep 30, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Nov 13, 2025. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 34–54 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Aug 3, 2026
34 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
—
|
-41
-14.1%
|
-0.38
+19.1%
|
|
May 4, 2026
34 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
-36
-19.1%
|
-0.34
+19.0%
|
|
Feb 23, 2026
54 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
—
|
-31
+16.0%
|
-0.30
+42.1%
|
|
Nov 13, 2025
44 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
—
|
-33
+5.7%
|
-0.33
+32.7%
|
|
Aug 12, 2025
43 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
—
|
-36
-13.7%
|
-0.47
-4.4%
|
|
May 5, 2025
35 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
—
|
-30
-20.0%
|
-0.42
-13.5%
|
|
Feb 18, 2025
49 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
—
|
-36
-28.2%
|
-0.51
-4.2%
|
|
Nov 12, 2024
43 days after quarter end
|
Q3 FY2024
ended Sep 30, 2024
|
—
|
-35
-35.7%
|
-0.49
-11.4%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ORIC (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South San Francisco, CA
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1796280
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.